Current Report Filing (8-k)
September 16 2020 - 8:51AM
Edgar (US Regulatory)
0001526119
false
0001526119
2020-09-16
2020-09-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 16, 2020
Verastem, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
|
001-35403
|
|
27-3269467
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
117 Kendrick Street, Suite 500, Needham, MA
|
|
02494
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (781) 292-4200
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common stock, $0.0001 par value per share
|
|
VSTM
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Other Events
On September 16, 2020,
Verastem, Inc. (the “Company”) issued a press release and posted a presentation, which the Company will be
presenting at the Second Annual RAS-Targeted Drug Development Summit on September 16, 2020 (the
“Presentation”), announcing updated clinical data from the low-grade serous ovarian cancer cohort of the ongoing
investigator-initiated Phase 1/2 FRAME study.
Copies of the press release and the Presentation are furnished hereto as Exhibits 99.1 and 99.2.
On September 16, 2020, the Company
also posted its corporate presentation, a copy of which is furnished hereto as Exhibit 99.3.
Item 9.01. Financial Statements and Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VERASTEM, INC.
|
|
|
Date: September 16, 2020
|
By:
|
/s/ Brian M. Stuglik
|
|
|
Brian M. Stuglik
|
|
|
Chief Executive Officer
|
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024